Table 3.

Combination immunotherapy of targeting MDSCs and ICB .

Tumor	ICB Target	Synergistic roles	Ref
CCA GC Cancer HNSCC TNBC PCa PDAC	ly6G/PD-1/CSF1R PD-1 PD-L1/HIF-1α CTLA-4 KAT6A/PD-1 BEZ235/mCRPC CXCR4/PD-1	To inhibition G-MDSC To inhibition resistance of ICI To inhibit tumor development To enhance sensitivity of CTLA-4 inhibition To reduce the recruitment of MDSCs To antitumor activity To reduce MDSC	(78) (80) (83) (84) (84) (85) (86, 87)

CCA, Cholangiocarcinoma; GC, Gastric carcinoma; HNSCC, Headneck squam ous Cell Carcinoma; TNBC, Triple-Negative Breast Cancer; PCa, prostate cancer; PDAC, Pancreatic ductal adenocarcinoma.